{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:26:44Z","timestamp":1792294004486,"version":"4.4.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Telethon Foundation","doi-asserted-by":"publisher","award":["TMDMHCSIITT"],"award-info":[{"award-number":["TMDMHCSIITT"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020","doi-asserted-by":"publisher","award":["666918"],"award-info":[{"award-number":["666918"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.bbadis.2019.165553","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T12:11:51Z","timestamp":1568290311000},"page":"165553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacological approaches to tackle NCLs"],"prefix":"10.1016","volume":"1866","author":[{"given":"Valerjans","family":"Kauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Dambrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Luis","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2019.165553_bb0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.0b013e31825f0547","article-title":"New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses","volume":"79","author":"Williams","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2019.165553_bb0010","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10545-017-0055-1","article-title":"High-content drug screening for rare diseases","volume":"40","author":"Bellomo","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbadis.2019.165553_bb0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nrneurol.2015.79","article-title":"Toward stem cell-based phenotypic screens for neurodegenerative diseases","volume":"11","author":"Khurana","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbadis.2019.165553_bb0020","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/hmg\/ddt596","article-title":"Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway","volume":"23","author":"Lojewski","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2019.165553_bb0025","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.7150\/thno.18456","article-title":"CRISPR genome engineering for human pluripotent stem cell research","volume":"7","author":"Chaterji","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.bbadis.2019.165553_bb0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jneuroim.2010.08.024","article-title":"Immunosuppression alters disease severity in juvenile batten disease mice","volume":"230","author":"Seehafer","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbadis.2019.165553_bb0035","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajmg.1320310631","article-title":"Selenium treatment in neuronal ceroid-lipofuscinosis","volume":"5","author":"Naidu","year":"1988","journal-title":"Am. J. Med. Genet. Suppl."},{"key":"10.1016\/j.bbadis.2019.165553_bb0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1152\/physiolgenomics.00100.2002","article-title":"Vitamin E deficiency and metabolic deficits in neuronal ceroid lipofuscinosis described by bioinformatics","volume":"11","author":"Griffin","year":"2002","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.bbadis.2019.165553_bb0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbrc.2011.09.019","article-title":"Protective potential of resveratrol against oxidative stress and apoptosis in batten disease lymphoblast cells","volume":"414","author":"Yoon","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbadis.2019.165553_bb0050","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1093\/hmg\/dds038","article-title":"The blood-brain barrier is disrupted in a mouse model of infantile neuronal ceroid lipofuscinosis: amelioration by resveratrol","volume":"21","author":"Saha","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2019.165553_bb0055","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/nn.3526","article-title":"Neuroprotection and lifespan extension in Ppt1(\u2212\/\u2212) mice by NtBuHA: therapeutic implications for INCL","volume":"16","author":"Sarkar","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bbadis.2019.165553_bb0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/hmg\/ddm324","article-title":"ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones","volume":"17","author":"Wei","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2019.165553_bb0065","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.bbadis.2015.05.011","article-title":"Genetics of the neuronal ceroid lipofuscinoses (batten disease)","volume":"1852","author":"Mole","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2019.165553_bb0070","doi-asserted-by":"crossref","first-page":"14361","DOI":"10.1074\/jbc.M114.621706","article-title":"Unbiased cell-based screening in a neuronal cell model of batten disease highlights an interaction between Ca2+ homeostasis, autophagy, and CLN3 protein function","volume":"290","author":"Chandrachud","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2019.165553_bb0075","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/ncb3114","article-title":"Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB","volume":"17","author":"Medina","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbadis.2019.165553_bb0080","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1174447","article-title":"A gene network regulating lysosomal biogenesis and function","volume":"325","author":"Sardiello","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2019.165553_bb0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.devcel.2011.07.016","article-title":"Transcriptional activation of lysosomal exocytosis promotes cellular clearance","volume":"21","author":"Medina","year":"2011","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbadis.2019.165553_bb0090","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3565","article-title":"Signals from the lysosome: a control centre for cellular clearance and energy metabolism","volume":"14","author":"Settembre","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbadis.2019.165553_bb0095","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.1204592","article-title":"TFEB links autophagy to lysosomal biogenesis","volume":"332","author":"Settembre","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2019.165553_bb0100","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1093\/hmg\/ddr306","article-title":"Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways","volume":"20","author":"Palmieri","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2019.165553_bb0105","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1083\/jcb.201501002","article-title":"MiT\/TFE transcription factors are activated during mitophagy downstream of Parkin and Atg5","volume":"210","author":"Nezich","year":"2015","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbadis.2019.165553_bb0115","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/emmm.201202176","article-title":"Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease","volume":"5","author":"Spampanato","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbadis.2019.165553_bb0120","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.bbadis.2013.05.014","article-title":"NCL disease mechanisms","volume":"1832","author":"Palmer","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2019.165553_bb0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(18)30368-5","article-title":"Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis","volume":"18","author":"Mole","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbadis.2019.165553_bb0130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/00480169.2002.36311","article-title":"Neuronal ceroid-lipofuscinosis in Borderdale sheep","volume":"50","author":"Jolly","year":"2002","journal-title":"N. Z. Vet. J."},{"key":"10.1016\/j.bbadis.2019.165553_bb0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nbd.2005.01.025","article-title":"Glial activation spreads from specific cerebral foci and precedes neurodegeneration in presymptomatic ovine neuronal ceroid lipofuscinosis (CLN6)","volume":"20","author":"Oswald","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbadis.2019.165553_bb0140","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.brainres.2004.07.030","article-title":"Late onset neurodegeneration in the Cln3\u2212\/\u2212 mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation","volume":"1023","author":"Pontikis","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.bbadis.2019.165553_bb0145","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1750-3639.2006.00002.x","article-title":"Activation of non-neuronal cells within the prenatal developing brain of sheep with neuronal ceroid lipofuscinosis","volume":"16","author":"Kay","year":"2006","journal-title":"Brain Pathol. Zurich Switz."},{"key":"10.1016\/j.bbadis.2019.165553_bb0150","doi-asserted-by":"crossref","first-page":"15575","DOI":"10.1523\/JNEUROSCI.3579-11.2011","article-title":"The role of attenuated astrocyte activation in infantile neuronal ceroid lipofuscinosis","volume":"31","author":"Macauley","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2019.165553_bb0155","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/brain\/awt020","article-title":"Immune cells perturb axons and impair neuronal survival in a mouse model of infantile neuronal ceroid lipofuscinosis","volume":"136","author":"Groh","year":"2013","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.bbadis.2019.165553_bb0160","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/glia.22962","article-title":"Sialoadhesin promotes neuroinflammation-related disease progression in two mouse models of CLN disease","volume":"64","author":"Groh","year":"2016","journal-title":"Glia"},{"issue":"97","key":"10.1016\/j.bbadis.2019.165553_bb0165","article-title":"Chronic oral administration of minocycline to sheep with ovine CLN6 neuronal ceroid lipofuscinosis maintains pharmacological concentrations in the brain but does not suppress neuroinflammation or disease progression","volume":"10","author":"Kay","year":"2013","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bbadis.2019.165553_bb0170","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/hmg\/11.12.1421","article-title":"An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder batten disease","volume":"11","author":"Chattopadhyay","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2019.165553_bb0175","first-page":"117","article-title":"Short-term administration of mycophenolate is well-tolerated in CLN3 disease (juvenile neuronal ceroid Lipofuscinosis)","volume":"43","author":"Augustine","year":"2019","journal-title":"JIMD Rep."},{"key":"10.1016\/j.bbadis.2019.165553_bb0180","doi-asserted-by":"crossref","first-page":"13077","DOI":"10.1523\/JNEUROSCI.2518-14.2014","article-title":"An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis","volume":"34","author":"Macauley","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2019.165553_bb0185","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/jnr.22763","article-title":"Altered glutamate receptor function in the cerebellum of the Ppt1\u2212\/\u2212 mouse, a murine model of infantile neuronal ceroid lipofuscinosis","volume":"90","author":"Finn","year":"2012","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bbadis.2019.165553_bb0190","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.neuint.2011.02.003","article-title":"Altered sensitivity of cerebellar granule cells to glutamate receptor overactivation in the Cln3(\u0394ex7\/8)-knock-in mouse model of juvenile neuronal ceroid lipofuscinosis","volume":"58","author":"Finn","year":"2011","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bbadis.2019.165553_bb0195","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.neuropharm.2010.10.010","article-title":"Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile batten disease","volume":"60","author":"Kov\u00e1cs","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbadis.2019.165553_bb0200","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.neuropharm.2012.05.040","article-title":"Age-dependent therapeutic effect of memantine in a mouse model of juvenile batten disease","volume":"63","author":"Kov\u00e1cs","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbadis.2019.165553_bb0205","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ana.24815","article-title":"Efficacy of phosphodiesterase-4 inhibitors in juvenile batten disease (CLN3)","volume":"80","author":"Aldrich","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2019.165553_bb0215","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1034\/j.1600-0854.2002.31102.x","article-title":"Secretory pathway quality control operating in Golgi, plasmalemmal, and endosomal systems","volume":"3","author":"Arvan","year":"2002","journal-title":"Traffic Cph. Den."},{"key":"10.1016\/j.bbadis.2019.165553_bb0220","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0955-0674(00)00233-7","article-title":"ER quality control: towards an understanding at the molecular level","volume":"13","author":"Ellgaard","year":"2001","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.bbadis.2019.165553_bb0225","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/adt.2011.0370","article-title":"Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders","volume":"9","author":"Valenzano","year":"2011","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.bbadis.2019.165553_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/BC.2008.009","article-title":"A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity","volume":"389","author":"Fan","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.bbadis.2019.165553_bb0235","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/emmm.200900036","article-title":"Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics","volume":"1","author":"Parenti","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbadis.2019.165553_bb0240","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbrc.2010.03.137","article-title":"Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile batten disease","volume":"395","author":"Dawson","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbadis.2019.165553_bb0245","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/humu.21624","article-title":"Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses","volume":"33","author":"Kousi","year":"2012","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bbadis.2019.165553_bb0250","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/hmg\/ddu428","article-title":"The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy","volume":"24","author":"Miller","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2019.165553_bb0255","doi-asserted-by":"crossref","first-page":"12508","DOI":"10.1073\/pnas.1605336113","article-title":"Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression","volume":"113","author":"Roy","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2019.165553_bb0260","first-page":"57","article-title":"Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis","author":"Sleat","year":"2001","journal-title":"Eur. J. Paediatr. Neurol. EJPN Off. J. Eur. Paediatr. Neurol. Soc. 5 Suppl A"},{"key":"10.1016\/j.bbadis.2019.165553_bb0265","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1093\/hmg\/ddt120","article-title":"The role of nonsense-mediated decay in neuronal ceroid lipofuscinosis","volume":"22","author":"Miller","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2019.165553_bb0270","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/hmg\/ddr088","article-title":"The batten disease gene CLN3 is required for the response to oxidative stress","volume":"20","author":"Tuxworth","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2019.165553_bb0275","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/cbf.2849","article-title":"N-acetylcysteine normalizes the urea cycle and DNA repair in cells from patients with batten disease","volume":"30","author":"Kim","year":"2012","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.bbadis.2019.165553_bb0280","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S1474-4422(14)70142-5","article-title":"Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study","volume":"13","author":"Levin","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbadis.2019.165553_bb0295","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/hmg\/ddl105","article-title":"Endoplasmic reticulum stress-induced caspase-4 activation mediates apoptosis and neurodegeneration in INCL","volume":"15","author":"Kim","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2019.165553_bb0300","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/hmg\/ddi451","article-title":"Palmitoyl-protein thioesterase-1 deficiency mediates the activation of the unfolded protein response and neuronal apoptosis in INCL","volume":"15","author":"Zhang","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2019.165553_bb0305","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/hmg\/ddl078","article-title":"Palmitoyl-protein thioesterase-1 deficiency leads to the activation of caspase-9 and contributes to rapid neurodegeneration in INCL","volume":"15","author":"Kim","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2019.165553_bb0310","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/hmg\/7.2.291","article-title":"Mutations in the palmitoyl-protein thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits","volume":"7","author":"Mitchison","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2019.165553_bb0315","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/86554","article-title":"Lysosomal ceroid depletion by drugs: therapeutic implications for a hereditary neurodegenerative disease of childhood","volume":"7","author":"Zhang","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbadis.2019.165553_bb0320","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10545-011-9446-x","article-title":"Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis","volume":"35","author":"Roberts","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"issue":"14338","key":"10.1016\/j.bbadis.2019.165553_bb0325","article-title":"mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases","volume":"8","author":"Palmieri","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2019.165553_bb0330","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/15548627.2018.1474313","article-title":"Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency","volume":"14","author":"Lotfi","year":"2018","journal-title":"Autophagy"},{"key":"10.1016\/j.bbadis.2019.165553_bb0335","doi-asserted-by":"crossref","first-page":"10309","DOI":"10.1074\/jbc.M114.610659","article-title":"Activation of peroxisome proliferator-activated receptor \u03b1 induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders","volume":"290","author":"Ghosh","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2019.165553_bb0340","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/jnc.13987","article-title":"Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis","volume":"141","author":"Ghosh","year":"2017","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2019.165553_bb0345","first-page":"207","article-title":"Bullous dermatosis of childhood induced by gemfibrozil","volume":"20","author":"Abtahi-Naeini","year":"2015","journal-title":"J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci."},{"key":"10.1016\/j.bbadis.2019.165553_bb0350","doi-asserted-by":"crossref","first-page":"38922","DOI":"10.1074\/jbc.M112.365148","article-title":"Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor \u03b1: implications for late infantile batten disease therapy","volume":"287","author":"Ghosh","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2019.165553_bb0355","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbadis.2019.165553_bb0360","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1021\/ci8000259","article-title":"Quantifying the relationships among drug classes","volume":"48","author":"Hert","year":"2008","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bbadis.2019.165553_bb0365","first-page":"132","article-title":"Exploring landscape of drug-target-pathway-side effect associations","volume":"2017","author":"Lim","year":"2018","journal-title":"AMIA Jt. Summits Transl. Sci. Proc. AMIA Jt. Summits Transl. Sci."},{"key":"10.1016\/j.bbadis.2019.165553_bb0370","first-page":"S33","article-title":"2018. Testing combinatorial therapies for juvenile batten disease. Mol. Genet. Metab","volume":"123","author":"Cooper","year":"2018","journal-title":"Lysosome"},{"issue":"Suppl. 1","key":"10.1016\/j.bbadis.2019.165553_bb0375","first-page":"682","article-title":"CLN2 disease (classic late infantile neuronal ceroid lipofuscinosis)","volume":"13","author":"Kohlsch\u00fctter","year":"2016","journal-title":"Pediatr. Endocrinol. Rev. PER"},{"key":"10.1016\/j.bbadis.2019.165553_bb0380","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-017-0771-8","article-title":"Cerliponase alfa: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443919302765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443919302765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:56:32Z","timestamp":1760417792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443919302765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0925443919302765"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2019.165553","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological approaches to tackle NCLs","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2019.165553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"165553"}}